Phenomenex Appoints New CEO
Kaveh Kahen, PhD, has been appointed president of Phenomenex, the Torrance, California-based separation science technology company, according to a press release. Kahen succeeds Matt Turner, who moved on from the Phenomenex presidency to pursue other opportunities, the company said.
Phenomenex operates within the Life Sciences group of Danaher Corporation, making this a homecoming of sorts for Kahen. After obtaining his PhD in analytical chemistry from The George Washington University, he began his professional career at Sciex, another Danaher Life Sciences holding.
Following his tenure at Sciex, Kahen held various leadership posts at PerkinElmer, according to the release, and more recently was CEO at Advion Interchim Scientific. Kahen designed and developed new technologies and instruments early in his career, and later as an executive gained a reputation for driving above-market growth in the fields of life sciences, analytical testing, and laboratory equipment, according to the release.
TD-GC–MS and IDMS Sample Prep for CRM to Quantify Decabromodiphenyl Ether in Polystyrene Matrix
April 26th 2024At issue in this study was the certified value of decabromodiphenyl ether (BDE 209) in a polystyrene matrix CRM relative to its regulated value in the EU Restriction of Hazardous Substances Directive.
LC–MS/MS-Based System Used to Profile Ceramide Reactions to Diseases
April 26th 2024Scientists from the University of Córdoba in Córdoba, Spain recently used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to comprehensively profile human ceramides to determine their reactions to diseases.
